Tuesday, June 20, 2023 4:42:59 PM
"Multiple large pharma companies have indicated interest in bringing the Mannin drugs to patients in markets around the world.
"We expect that at least one major strategic deal will be announced by Q1 of 2023 and additional transformative economic transactions later in 2023, further validating the MRI drug pipeline and its blockbuster potential.
"These would be very significant value creating events for both QBIO and Mannin shareholders. QBIO is so proud to have been an integral part of this development from the beginning."
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM